While the observed relative risk reduction in insulin initiation or intensification was more modest compared with that seen in other SGLT2 inhibitor trials, even moderate effects remain clinically relevant given the limited glucose-lowering options available in advanced CKD and the adverse effects associated with insulin use. The gene discussed is INS; the disease is chronic kidney disease.